For psychotherapists and inner explorers, an expansive, multidimensional odyssey into the history, practice, and potential of psychedelic healing Now that the stigmas against psychedelic medicine are finally lifting, there’s a lot of curiosity—and confusion—about these powerful compounds. How can psychedelics be used safely? What are the risks? Can they truly help heal the wide variety of conditions that has garnered such international attention? In Psychedelic Revival, Sean Lawlor invites you on a deep dive into the science, spirituality, and practice of psychedelic healing—a revival of both the first wave of pre-1960s research and ancient healing traditions with plant medicines. Join this respected author and researcher to gain a full-spectrum understanding of the possibilities and limits of psychedelics, including: • The Western history of psychedelic medicine and recreational use • The millennium-spanning legacy of Indigenous plant medicine traditions • In-depth chapters on psilocybin, LSD, MDMA, ketamine, mescaline, ibogaine, peyote, ayahuasca, DMT, and more • Practical insights, from microdosing to psychedelic-assisted psychotherapy to transformative mystical experiences • The shadow dimensions of psychedelics—bad trips, scientific stigmatization, inequality of access, and many other essential topics Informed by solid research and direct wisdom from perceptive firsthand accounts, Lawlor guides you into the psychedelic landscape, covering treatment methods, realistic benefits, and the legitimate perils psychedelics can induce. Along the way, he shares exclusive interviews with luminaries such as Michael Pollan, Rick Doblin, Camille Barton, Carl Hart, Jim Fadiman, Rick Strassman, Natalie Ginsberg, Sandor Iron Rope, and many more. Psychedelics have tremendous healing potential, yet all evocative modalities should be handled with care. To make good choices, we need quality information about the prospects and pitfalls of these emerging therapeutic tools. Psychedelic Revival is an invaluable resource for navigating this exciting frontier in Western healing.

A vivid analysis of the history and revival of clinical psychedelic science Psychedelic drugs are making a comeback. In the mid-twentieth century, scientists actively studied the potential of drugs like LSD and psilocybin for treating mental health problems. After a decades-long hiatus, researchers are once again testing how effective these drugs are in relieving symptoms for a wide variety of psychiatric conditions, from depression and obsessive–compulsive disorder to posttraumatic stress disorder and substance addiction. In Acid Revival, Danielle Giffort examines how this new generation of researchers and their allies are working to rehabilitate psychedelic drugs and to usher in a new era of psychedelic medicine. As this team of researchers and mental health professionals revive the field of psychedelic science, they are haunted by the past and by one person in particular: psychedelic evangelist Timothy Leary. Drawing on extensive archival research and interviews with people working on scientific psychedelia, Giffort shows how today’s researchers tell stories about Leary as an “impure” scientist and perform his antithesis to address a series of lingering dilemmas that threaten to rupture their budding legitimacy. Acid Revival presents new information about the so-called psychedelic renaissance and highlights the cultural work involved with the reassembly of dormant areas of medical science. This colorful and accessible history of the rise, fall, and reemergence of psychedelic medicine is infused with intriguing narratives and personalities—a story for popular science aficionados as well as for scholars of the history of science and medicine.

Neuropsychedelia examines the revival of psychedelic science since the "Decade of the Brain." After the breakdown of this previously prospering area of psychopharmacology, and in the wake of clashes between counterculture and establishment in the late 1960s, a new generation of hallucinogen researchers used the hype around the neurosciences in the 1990s to bring psychedelics back into the mainstream of science and society. This book is based on anthropological fieldwork and philosophical reflections on life and work in two laboratories that have played key roles in this development: a human lab in Switzerland and an animal lab in California. It sheds light on the central transnational axis of the resurgence connecting American psychedelic culture with the home country of LSD. In the borderland of science and religion, Neuropsychedelia explores the tensions between the use of hallucinogens to model psychoses and to evoke spiritual experiences in laboratory settings. Its protagonists, including the anthropologist himself, struggle to find a place for the mystical under conditions of late-modern materialism.

Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca • Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker. Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago by the U.S. government as well as offering non-technical summaries of the most recent studies with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health. Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field, the growing threat of overmedication by the pharmaceutical industry, and the links between psychiatric drugs and mental illness. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.

Cited by the L.A. Weekly as "the culture's foremost spokesman for the psychedelic experience," Terrence McKenna is an underground legend as a brilliant raconteur, adventurer, and expert on the experiential use of mind-altering plants. In these essays, interviews, and narrative adventures, McKenna takes us on a mesmerizing journey deep into the Amazon as well as into the hidden recesses of the human psyche and the outer limits of our culture, giving us startling visions of the past and future.

Psychedelic Shamanism presents the spiritual and shamanic properties of psychotropic plants and discusses how they can be used to understand the structure of human consciousness. Author Jim DeKorne offers authoritative information about the cultivation, processing, and correct dosages for various psychotropic plant substances including the belladonna alkaloids, d-lysergic acid amide, botanical analogues of LSD, mescaline, ayahuasca, DMT, and psilocybin. Opening with vivid descriptions of the author’s personal experiences with psychedelic drugs, the book describes the parallels that exist among shamanic states of consciousness, the use of psychedelic catalysts, and the hidden structure of the human psyche. DeKorne suggests that psychedelic drugs allow us to examine the shamanic dimensions of reality. This worldview, he says, is ubiquitous across space, time, and culture, with individuals separated by race, distance, and culture routinely describing the same core reality that provides powerful evidence of the dimensional nature of consciousness itself. The book guides the reader through the imaginal realm underlying our awareness, a world in which spiritual entities exist to reconnect us with ourselves, humanity, and our planet. Accurate drawings of plants, including peyote, Salvia divinorum, and San Pedro, enhance the book’s usefulness.

The rise—and fall—of research into the therapeutic potential of LSD. After LSD arrived in the United States in 1949, the drug's therapeutic promise quickly captured the interests of psychiatrists. In the decade that followed, modern psychopharmacology was born and research into the drug's perceptual and psychological effects boomed. By the early 1960s, psychiatrists focused on a particularly promising treatment known as psychedelic therapy: a single, carefully guided, high-dose LSD session coupled with brief but intensive psychotherapy. Researchers reported an astounding 50 percent success rate in treating chronic alcoholism, as well as substantial improvement in patients suffering from a range of other disorders. Yet despite this success, LSD officially remained an experimental drug only. Research into its effects, psychological and otherwise, dwindled before coming to a close in the 1970s. In The Trials of Psychedelic Therapy, Matthew Oram traces the early promise and eventual demise of LSD psychotherapy in the United States. While the common perception is that LSD's prohibition terminated legitimate research, Oram draws on files from the Food and Drug Administration and the personal papers of LSD researchers to reveal that the most significant issue was not the drug's illegality, but the persistent question of its efficacy. The landmark Kefauver-Harris Drug Amendments of 1962 installed strict standards for efficacy evaluation, which LSD researchers struggled to meet due to the unorthodox nature of their treatment. Exploring the complex interactions between clinical science, regulation, and therapeutics in American medicine, The Trials of Psychedelic Therapy explains how an age of empirical research and limited government oversight gave way to sophisticated controlled clinical trials and complex federal regulations. Analyzing the debates around how to understand and evaluate treatment efficacy, this book will appeal to anyone with an interest in LSD and psychedelics, as well as mental health professionals, regulators, and scholars of the history of psychiatry, psychotherapy, drug regulation, and pharmaceutical research and development.